Back to search

Article

Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

2024-02-15

Abstract excerpt

<h4>Background</h4> Reliable biomarkers for precision medicine in metastatic colorectal cancer (mCRC) are needed. Blood biomarkers like chemokines may offer insights into overall tumor burden, yet, few prospective studies explore chemokine dynamics during treatment. This study investigates the behavior of a chemokine panel in mCRC patients during first-line oxaliplatin-based treatment, aiming to identify predictiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
55c9fb85-0974-5345-91f6-98e42de21a1c
DOI
10.1101/2024.02.15.24302875
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based TreatmentDOI 10.1101/2024.02.15.24302875
Select a neighboring publication to make it the new centre.